Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations
E. Rosalie Witjas‐Paalberends(Amsterdam UMC Location VUmc), Jolanda van der Velden(Amsterdam University Medical Centers), Cristobal G. dos Remedios(The University of Sydney), Michelle Michels(Erasmus MC), Arend F. L. Schinkel(Erasmus MC), Ger J.M. Stienen(Amsterdam UMC Location VUmc), Hendrik J. Harms(Amsterdam UMC Location VUmc), Paul Knaapen(Amsterdam University Medical Centers), Alexa M.C. Vermeer(Academic Medical Center), Corrado Poggesi(University of Florence), Imke Christiaans(Academic Medical Center), Marjon van Slegtenhorst(Erasmus MC), Adriaan A. Lammertsma(Amsterdam UMC Location VUmc), Albert C. van Rossum(Amsterdam UMC Location VUmc), Tjeerd Germans(Turku PET Centre), Carolyn Y. Ho(Brigham and Women's Hospital), Ahmet Güçlü(Amsterdam UMC Location VUmc), Arthur A.M. Wilde
Cited by 125
Related Papers
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
Anatomic Versus Physiologic Assessment of Coronary Artery Disease
|Journal of the American College of Cardiology|2013|563
Risk Factors for Malignant Ventricular Arrhythmias in Lamin A/C Mutation Carriers
|Journal of the American College of Cardiology|2012|516